OR WAIT null SECS
August 03, 2021
Dosage form priorities are shifting to focus on user-friendliness, leading to greater engagement with outsourcing partners earlier in development timelines.
Amorphous solid dispersions can overcome the pH effect encountered with oral oncology medications.
August 02, 2021
Collaborative partnerships can foster success in formulation development projects.
Recent research has highlighted the underlying mechanisms of amorphous solid dispersions and theory behind the formation of drug-rich phases.
August 01, 2021
The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.
Developers might invest in small-scale equipment to produce packaging for stability studies in-house, or they might outsource production. Manufacturers should consider the benefits and risks to both approaches.
July 03, 2021
The purpose of this research was to formulate modified liquisolid compacts (MLSC) of RLX for improved dissolution in immediate-release tablet formulations.
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.
Bi-layer tablets are an under-utilized option that can be employed to help reduce treatment burden, but their formulation is more complex than for conventional monolayer products.
June 30, 2021
Modified-release dosage forms present new opportunities for drug developers and can help overcome challenges, such as short biological half-life or poor bioavailability due to degradation in the stomach.